Dynamics of total, linear nonintegrated, and integrated HIV-1 DNA in vivo and in vitro
- PMID: 18248304
- DOI: 10.1086/525283
Dynamics of total, linear nonintegrated, and integrated HIV-1 DNA in vivo and in vitro
Abstract
Background: In patients infected with human immunodeficiency virus type 1 (HIV-1), HIV-1 DNA persists during highly active antiretroviral treatment, reflecting long-lived cellular reservoirs of HIV-1. Recent studies report an association between HIV-1 DNA levels, disease progression, and treatment outcome. However, HIV-1 DNA exists as distinct molecular forms that are not distinguished by conventional assays.
Methods: We analyzed HIV-1 RNA levels in plasma, CD4 cell counts, and levels of integrated and nonintegrated HIV-1 DNA in peripheral blood mononuclear cells (PBMCs) from patients with early or chronic infection before and during antiretroviral treatment. We also studied HIV-1 DNA decay in primary CD4 T cells infected in vitro. HIV-1 DNA was analyzed using an assay that is unaffected by the location of HIV-1 integration sites.
Results: HIV-1 RNA levels and total HIV-1 DNA levels decayed rapidly in patients during receipt of suppressive antiretroviral therapy. Ratios of total HIV-1 DNA levels to integrated HIV-1 DNA levels were high before initiation of therapy but diminished during therapy. Levels of linear nonintegrated HIV-1 DNA decayed rapidly in vitro (t (1/2) = 1- 4.8 days).
Conclusion: Total HIV-1 DNA decays rapidly with suppression of virus replication in vivo. Clearance of HIV-1 DNA during the first 6 months of therapy reflects a disproportionate loss of nonintegrated HIV-1 DNA genomes, suggesting that levels of total HIV-1 DNA in PBMCs after prolonged virus suppression largely represent integrated HIV-1 genomes.
Similar articles
-
Short Intracellular HIV-1 Transcripts as Biomarkers of Residual Immune Activation in Patients on Antiretroviral Therapy.J Virol. 2016 May 27;90(12):5665-5676. doi: 10.1128/JVI.03158-15. Print 2016 Jun 15. J Virol. 2016. PMID: 27030274 Free PMC article.
-
Persistence of HIV-1 transcription in peripheral-blood mononuclear cells in patients receiving potent antiretroviral therapy.N Engl J Med. 1999 May 27;340(21):1614-22. doi: 10.1056/NEJM199905273402102. N Engl J Med. 1999. PMID: 10341273 Clinical Trial.
-
Quantification of integrated and total HIV-1 DNA after long-term highly active antiretroviral therapy in HIV-1-infected patients.AIDS. 1999 Jun 18;13(9):1045-9. doi: 10.1097/00002030-199906180-00007. AIDS. 1999. PMID: 10397534
-
The role of integration and clonal expansion in HIV infection: live long and prosper.Retrovirology. 2018 Oct 23;15(1):71. doi: 10.1186/s12977-018-0448-8. Retrovirology. 2018. PMID: 30352600 Free PMC article. Review.
-
Genotypic Resistance Testing of HIV-1 DNA in Peripheral Blood Mononuclear Cells.Clin Microbiol Rev. 2022 Dec 21;35(4):e0005222. doi: 10.1128/cmr.00052-22. Epub 2022 Sep 14. Clin Microbiol Rev. 2022. PMID: 36102816 Free PMC article. Review.
Cited by
-
Effect of raltegravir-containing intensification on HIV burden and T-cell activation in multiple gut sites of HIV-positive adults on suppressive antiretroviral therapy.AIDS. 2010 Oct 23;24(16):2451-60. doi: 10.1097/QAD.0b013e32833ef7bb. AIDS. 2010. PMID: 20827162 Free PMC article.
-
Impact of Different Antiretroviral Strategies on Total HIV-DNA Level in Virologically Suppressed HIV-1 Infected Patients.Curr HIV Res. 2017;15(6):448-455. doi: 10.2174/1570162X16666171206121026. Curr HIV Res. 2017. PMID: 29210661 Free PMC article.
-
Factors associated with unquantifiable total HIV-1 DNA in peripheral blood in persons living with HIV: An observational study.J Virus Erad. 2024 Mar 28;10(1):100370. doi: 10.1016/j.jve.2024.100370. eCollection 2024 Mar. J Virus Erad. 2024. PMID: 38596322 Free PMC article.
-
On the Death Rate of Abortively Infected Cells: Estimation from Simian-Human Immunodeficiency Virus Infection.J Virol. 2017 Aug 24;91(18):e00352-17. doi: 10.1128/JVI.00352-17. Print 2017 Sep 15. J Virol. 2017. PMID: 28679753 Free PMC article.
-
Evaluation of HIV-1 reservoir size and broadly neutralizing antibody susceptibility in acute antiretroviral therapy-treated individuals.AIDS. 2022 Feb 1;36(2):205-214. doi: 10.1097/QAD.0000000000003088. AIDS. 2022. PMID: 34586088 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
- AI027670/AI/NIAID NIH HHS/United States
- AI027763/AI/NIAID NIH HHS/United States
- AI029164/AI/NIAID NIH HHS/United States
- AI029193/AI/NIAID NIH HHS/United States
- AI034214/AI/NIAID NIH HHS/United States
- AI038858/AI/NIAID NIH HHS/United States
- AI043638/AI/NIAID NIH HHS/United States
- AI043752/AI/NIAID NIH HHS/United States
- AI047745/AI/NIAID NIH HHS/United States
- AI055388/AI/NIAID NIH HHS/United States
- AI060530/AI/NIAID NIH HHS/United States
- AI062435/AI/NIAID NIH HHS/United States
- NS051132/NS/NINDS NIH HHS/United States
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials